{
    "eid": "2-s2.0-85164759740",
    "title": "CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2",
    "cover-date": "2023-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Sedthawut Laotee",
        "Methawee Duangkaew",
        "Araya Jivapetthai",
        "Kittipan Tharakhet",
        "Papatsara Kaewpang",
        "Eakachai Prompetchara",
        "Supaporn Phumiamorn",
        "Sompong Sapsutthipas",
        "Sakalin Trisiriwanich",
        "Thitiporn Somsaard",
        "Sittiruk Roytrakul",
        "Parichat Duangkhae",
        "Boonsri Ongpipattanakul",
        "Patanachai Limpikirati",
        "Natapol Pornputtapong",
        "Wanatchaporn Arunmanee"
    ],
    "citedby-count": 0,
    "ref-count": 68,
    "ref-list": [
        "An mRNA Vaccine against SARS-CoV-2-Preliminary Report",
        "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine",
        "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial",
        "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",
        "Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine",
        "Safety and immunogenicity of a recombinant tandemrepeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials",
        "Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial",
        "SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates",
        "Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses",
        "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity",
        "Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice",
        "Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4",
        "Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine",
        "A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS",
        "A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity",
        "Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2",
        "Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine",
        "Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452",
        "A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates",
        "A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models",
        "Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial",
        "A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452",
        "Vaccine adjuvants: putting innate immunity to work",
        "A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines",
        "Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design",
        "Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines",
        "Vaccine adjuvants: current state and future trends",
        "The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement",
        "Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development",
        "Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptorbinding domain as an antigen",
        "Intranasal vaccination with recombinant receptorbinding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines",
        "A statistically defined endpoint titer determination method for immunoassays",
        "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction",
        "Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates",
        "Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection",
        "SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung",
        "A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation",
        "Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology",
        "Fc-fusion proteins: new developments and future perspectives",
        "Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics",
        "SARS-CoV-2 RBD219-N1C1: A yeastexpressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice",
        "Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation",
        "COVID-19 Vaccines: Should We Fear ADE?",
        "A New Vaccine to Battle Covid-19",
        "Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data",
        "Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus",
        "A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge",
        "Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells",
        "Interleukin-12 profoundly upregulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo",
        "Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses",
        "Adjuvantation helps to optimise COVID-19 vaccine candidate",
        "CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge",
        "A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1",
        "Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant",
        "Safety and tolerability evaluation of the use of Montanide ISA\u212251 as vaccine adjuvant: A systematic review",
        "QuilA-Adjuvanted T. gondii Lysate Antigens Trigger Robust Antibody and IFN\u03b3(+) T Cell Responses in Pigs Leading to Reduction in Parasite DNA in Tissues Upon Challenge Infection",
        "Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19",
        "Safety and Efficacy of NVXCoV2373 Covid-19 Vaccine",
        "Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials",
        "The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism",
        "Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice",
        "Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine",
        "Immunology and efficacy of MF59-adjuvanted vaccines",
        "Innate immune response in Th1- and Th2-dominant mouse strains"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nontaburi",
            "@id": "60015728",
            "affilname": "Thailand Ministry of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015728",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60015572",
            "affilname": "Thailand Government Pharmaceutical Organization",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015572",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}